Dreger, Peter, Michallet, Mauricette, Bosman, Paul, Dietrich, Sascha, Sobh, Mohamad, Boumendil, Ariane, Nagler, Arnon, Scheid, Christof, Cornelissen, Jan, Niederwieser, Dietger, Mueller, Lutz, Vandenberghe, Elizabeth, Scortechini, Ilaria, Schoemans, Helene, Andersen, Niels S., Finke, Juergen, Russo, Domenico, Ljungman, Per, Passweg, Jakob, van Gelder, Michel, Durakovic, Nadira, Labussiere-Wallet, Helene, Berg, Tobias ORCID: 0000-0003-2668-0449, Wulf, Gerald, Bethge, Wolfgang, Bunjes, Donald, Stilgenbauer, Stefan, Canepari, Maria Elisa, Schaap, Michel, Fox, Christopher P., Kroeger, Nicolaus, Montoto, Silvia and Schetelig, Johannes (2019). Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties. Bone Marrow Transplant., 54 (1). S. 44 - 53. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365

Full text not available from this repository.

Abstract

The aim of this retrospective study was to investigate the safety and efficacy of allogeneic hematopoietic cell transplantation (alloHCT) in patients pre-treated with ibrutinib. Eligible were patients aged >18 years allotransplanted for chronic lymphocytic leukemia (CLL) or mantle cell lymphoma (MCL) after prior exposure to ibrutinib who were registered with the EBMT registry. Seventy patients (CLL 48, MCL 22) were included. At the time of alloHCT, 73% of the patients were ibrutinib responsive. All patients except one engrafted, and acute GVHD grade 2-4 (3-4) was observed in 49% (12%) of 68 evaluable patients. The cumulative incidence of chronic GVHD was 54% 1 year after transplant. In the CLL group, 12-month non-relapse mortality, relapse incidence (RI), progression-free survival (PFS), and overall survival (OS) were 10, 30, 60, and 72%, respectively, and in the MCL group 5, 19, 76, and 86%, respectively. Pre-transplant ibrutinib failure and poor performance status predicted inferior RI, PFS and OS in the CLL group. In conclusion, ibrutinib does not affect the safety of a subsequent alloHCT. While the relatively high post-transplant relapse risk in ibrutinib-exposed patients with CLL deserves further study, in patients with MCL consolidating disease responses to ibrutinib with alloHCT seems to be a promising option.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Dreger, PeterUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Michallet, MauricetteUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bosman, PaulUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Dietrich, SaschaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Sobh, MohamadUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Boumendil, ArianeUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Nagler, ArnonUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Scheid, ChristofUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Cornelissen, JanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Niederwieser, DietgerUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Mueller, LutzUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Vandenberghe, ElizabethUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Scortechini, IlariaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schoemans, HeleneUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Andersen, Niels S.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Finke, JuergenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Russo, DomenicoUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ljungman, PerUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Passweg, JakobUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
van Gelder, MichelUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Durakovic, NadiraUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Labussiere-Wallet, HeleneUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Berg, TobiasUNSPECIFIEDorcid.org/0000-0003-2668-0449UNSPECIFIED
Wulf, GeraldUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bethge, WolfgangUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bunjes, DonaldUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Stilgenbauer, StefanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Canepari, Maria ElisaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schaap, MichelUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Fox, Christopher P.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kroeger, NicolausUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Montoto, SilviaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schetelig, JohannesUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-140281
DOI: 10.1038/s41409-018-0207-4
Journal or Publication Title: Bone Marrow Transplant.
Volume: 54
Number: 1
Page Range: S. 44 - 53
Date: 2019
Publisher: NATURE PUBLISHING GROUP
Place of Publication: LONDON
ISSN: 1476-5365
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
TERM-FOLLOW-UP; HIGH-RISK CLL; EUROPEAN-SOCIETY; DISEASE-CONTROL; THERAPY; FAILURE; SURVIVAL; OUTCOMES; BLOOD; ERAMultiple languages
Biophysics; Oncology; Hematology; Immunology; TransplantationMultiple languages
Refereed: Yes
URI: http://kups.ub.uni-koeln.de/id/eprint/14028

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item